Examples of this include the use of v-erb-b2 erythroblastic leukaemia viral oncogene homolog 2 (HER2) blocking antibodies in breast cancer, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitor in lung cancer [5, 6], specific v-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitors in melanoma [7], and selection of EGFR blocking antibodies for the treatments of v-Ki-ras Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type colon cancers [8]. This evidence concerns the gene BRAF and colonic neoplasm.